The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis

被引：0
|
作者：
Kongju Wu
Ming Yi
Shuang Qin
Qian Chu
Xinhua Zheng
Kongming Wu
机构：
[1] Medical School of Pingdingshan University,Department of Clinical Medicine
[2] Huazhong University of Science and Technology,Department of Oncology, Tongji Hospital of Tongji Medical College
来源：
Experimental Hematology & Oncology | / 8卷
关键词：
Immunotherapy; PD-1; PD-L1; CTLA-4; Immune checkpoint inhibitor; Combination therapy; Meta-analysis; Systematic review;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Efficacy and safety of PD-1/PD-L1 plus CTLA-4 antibodies ± other therapies in lung cancer: a systematic review and meta-analysis
    Shen, Xiang
    Huang, Shangke
    Xiao, Hua
    Zeng, Shan
    Liu, Jiexing
    Ran, Zhuolan
    Xiong, Bin
    EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2023, 30 (01) : 3 - 8
  • [12] Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors)
    Wu, Yingcheng
    Ju, Qianqian
    Jia, Keren
    Yu, Jingyan
    Shi, Hui
    Wu, Huiqun
    Jiang, Maorong
    INTERNATIONAL JOURNAL OF CANCER, 2018, 143 (01) : 45 - 51
  • [13] Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
    Feng, Yuqian
    Jin, Huimin
    Guo, Kaibo
    Xiang, Yuying
    Zhang, Yiting
    Du, Wurong
    Shen, Minhe
    Ruan, Shanming
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [14] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
    Rotte, Anand
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
  • [15] Combination of CTLA-4 and PD-1 blockers for treatment of cancer
    Anand Rotte
    Journal of Experimental & Clinical Cancer Research, 38
  • [16] Treatment-related adverse events of PD-1/PD-L1 inhibitors combined with CTLA-4 inhibitors in clinical trials: a meta-analysis
    Mi, Ze
    Zhang, Yunshu
    Feng, Zhichao
    Liu, Jiahao
    Wu, Jianmin
    Tan, Hongpei
    Ma, Xiaoqian
    Liu, Zhenguo
    Rong, Pengfei
    ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY, 2022, 50 (01) : 301 - 309
  • [17] Multiomic meta-analysis of differential response to PD-1 and CTLA-4 blockade in metastatic melanoma
    Huang, Amy Y.
    Vokes, Natalie
    Ricker, Cora
    Aprati, Tyler
    Robitschek, Emily
    Yang, Jiekun
    Ho, Li-Lun
    Galani, Kyriakitsa
    Burke, Kelly P.
    Tarantino, Giuseppe
    Chen, Jiajia
    Sharpe, Arlene H.
    Van Allen, Eliezer M.
    Kellis, Manolis
    Boland, Genevieve M.
    Liu, David
    CANCER RESEARCH, 2023, 83 (07)
  • [18] A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
    Song, Qi
    Jiang, Meiling
    Pan, Xinrong
    Zhou, Guanyue
    Zhang, Xiaomeng
    IMMUNOBIOLOGY, 2024, 229 (06)
  • [19] Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.
    Ali, Faisal
    Hussain, Maryam R.
    Deep, Aman
    Abu-Sbeih, Hamzah
    Alrifai, Taha
    Myint, Phyo Thazin
    Gong, Zimu
    Kozma, Kelley Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [20] The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis
    Nie, Run-Cong
    Zhao, Chong-Bang
    Xia, Xiao-Wei
    Luo, Ying-Shan
    Wu, Ting
    Zhou, Zhi-Wei
    Yuan, Shu-Qiang
    Wang, Yun
    Li, Yuan-Fang
    BIOMED RESEARCH INTERNATIONAL, 2020, 2020
12345